Glaukos Sales Surge, Profitability Sinks Amidst Transition Costs
Event summary
- Glaukos reported Q4 2025 net sales of $143.1 million, a 36% year-over-year increase.
- Full-year 2025 net sales reached $507.4 million, up 32% year-over-year.
- The company reaffirmed its 2026 net sales guidance of $600 million to $620 million.
- GAAP net loss for Q4 2025 was $133.7 million, or ($2.32) per diluted share, significantly impacted by a $112.9 million impairment charge.
The big picture
Glaukos' strong revenue growth reflects the increasing demand for its innovative ophthalmic therapies, particularly in the MIGS and dropless drug delivery segments. However, the substantial impairment charge and declining profitability highlight the challenges of integrating acquired assets and managing operating expenses during a period of rapid expansion. The company's future success will depend on its ability to translate revenue growth into sustainable profitability and effectively manage the complexities of its expanding product portfolio.
What we're watching
- Margin Pressure
- The significant drop in GAAP gross margin, coupled with substantial operating losses, warrants close scrutiny of Glaukos' cost management strategies and ability to maintain profitability as it scales.
- Epioxa Adoption
- The success of Glaukos' 2026 guidance hinges on the rapid and widespread adoption of Epioxa, and whether it can offset the costs associated with its transition and integration.
- Growth Sustainability
- While Glaukos has demonstrated impressive revenue growth, the pace at which it can sustain this momentum will depend on its ability to navigate competitive pressures and expand into new markets.
Related topics